Nergiz Zorbozan

Nergiz Zorbozan

Auto-generated profile, based on publicly available information

Nergiz Zorbozan

İzmir Kemalpaşa Devlet Hastanesi

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in Biochemia Medica
Verified
Journal Article
Open access
PDF file
OZOrçun Zorbozan
Orçun Zorbozan
NZNergiz Zorbozan
Nergiz Zorbozan
IntroductionThe aim of the study was to determine the current state of laboratory’s extra-analytical phase performance by calculating preanalytical and postanalytical phase quality indicators (QIs) and sigma values and to compare obtained data according to desired quality specifications and sigma values reported by The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Working Group – Laboratory errors and Patient Safety. Materials and methodsPreanalytical and postanalytical phase data were obtained through laboratory information system. Rejected samples in preanalytical phase were grouped according to reasons for rejection and frequencies were calculated both monthly and for 2019. Sigma values were calculated according to “short term sigma” table. ResultsThe number of rejected samples in laboratory was 643 out of 191,831 in 2019. Total preanalytical phase rejection frequency was 0.22%. According to the reasons for rejection, QIs and sigma values were: “Samples with excessive transportation time”: 0.0036 and 5.47; “Samples collected in wrong container” 0.02 and 5.11. In December, QIs and sigma values were: “Samples with excessive transportation time”: 0.01 and 5.34; “Samples collected in wrong container”: 0.03 and 4.98. The postanalytical QIs and sigma values were: “Reports delivered outside the specified time”: 0.34 and 4.21; “Turn around time of potassium”: 56 minute and 3.84, respectively. There were no errors in “Critical values of inpatients and outpatients notified after a consensually agreed time”. ConclusionsExtra-analytical phase was evaluated by comparing it with the latest quality specifications and sigma values which will contribute to improving the quality of laboratory medicine.

30 January 2018 in Turkish Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
NZNergiz Zorbozan
Nergiz Zorbozan
SDSüleyman Demir
Süleyman Demir
VÇVeli Çobankara
Veli Çobankara
Objective: We aimed to evaluate the relationship among TNFα, sTNFR1, sTNFR2, sIL2R, IL6, neopterin and disease activity in ankylosing spondylitis (AS). Materials and methods: TNFα, sTNFR1, sTNFR2, sIL2R, IL6 and neopterin were measured in patients and controls. Patients were grouped according to disease activity and medication. Results: Neopterin and sTNFR1 were not different while TNFα, sTNFR2, sIL2R and IL6 were high in patients than controls. There was no difference between active and inactive patients for TNFα, sIL2R and IL6. sTNFR2 was significantly lower in active patients. There was no relationship between CRP positivity and disease activity. AS patient groups are; 1: TNF blockers, 2: nonsteroidal anti-inflammatory drugs (NSAIDs), 3: disease modifying anti-rheumatic drugs (DMARDs), 4: TNF blockers and NSAIDs, 5: DMARDs and NSAIDs. sTNFR2 was significantly lower in active patients than in inactive, in Group 1. ESR levels were significantly lower in inactive patients compared to active in group 3 and 4. There was no significant association between CRP positivity and disease activity. Conclusion: According to our study, CRP is insufficient in evaluating AS disease activity. ESR can be useful in evaluating the disease activity. sTNFR2 might be useful as a biological indicator of disease activity in AS treated with TNF inhibitors alone.

15 July 2019 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
OZOrçun Zorbozan
Orçun Zorbozan
NZNergiz Zorbozan
Nergiz Zorbozan
NTNevin Turgay
Nevin Turgay
Laboratories have important role in decisions related to the patient. Laboratory performance needs to be evaluated to ensure accurate and sustainable laboratory results. Total test process consists of pre-analytical, analytical and post-analytical sub-processes. Most of the laboratory errors occur in pre-analytical process, which is mostly outside the laboratory, and this important situation has to be monitored by laboratory specialists. Although the standard statistical methods in which the frequency is evaluated can reveal which error is more than the others, they cannot determine which error is needed due to the absence of accepted target values. The decision to intervene in errors can only be made according to the targets by evaluating with methods such as six-sigma and quality indicators. Six-sigma method; is a quality management tool that provides information about process performance. Low sigma level indicates variability or errors in the relevant process. Quality indicators have been developed to measure quality and efficiency of laboratory processes. Use of quality indicators is effective in reducing errors, increasing patient safety and helping to meet ISO-15189 requirements. In this study, it was aimed to evaluate pre-analytical process performance in Parasitology Direct Diagnosis Laboratory of Ege University Faculty of Medicine according to the quality targets of International Federation of Clinical Chemistry and Laboratory Medicine Working Group on Laboratory Errors and Patient Safety (IFCC WG-LEPS) and the six-sigma method. The data of rejected samples in our laboratory during the period 2014-2017 were obtained retrospectively from laboratory information system. Errors were classified using laboratory errors classification system. Quality indicators were calculated for each error category and assessed according to IFCC WG-LEPS quality targets. Pre-analytical sigma level was calculated for each year. Our pre-analytical process sigma goal was 4.6. Sigma levels were calculated according to the reasons of rejection and Pareto analysis was performed. All of the rejected samples were pre-analytical process errors. Unacceptable quality indicators according to the IFCC WG-LEPS targets were found as "insufficient sample" in 2015; "insufficient sample" and "inappropriate sample tube" in 2016 and 2017. Our pre-analytical process sigma levels according to the rejection reasons were found to be 4.39, 4.31, 4.11, 4.17, respectively in 2014- 2017. "Improper test request" in 2014, and "insufficient sample" in 2015-2017 had sigma levels below 4.6. In addition "improper test request" in 2014, and "insufficient sample" in 2015, 2016 and 2017 were noticeable in Pareto analysis. In this study, pre-analysis process was evaluated with six sigma method and quality indicators and the areas open for improvement were determined quantitatively. We found "insufficient sample", "improper test request" and "inappropriate sample tube" indicators as inappropriate according to our target values with both quality indicators and six-sigma methods. For this reason, we have planned video conference training focused on error sources for all employees. We consider that risk and number of errors will be reduced and efficiency of whole test process can be increased by evaluating pre-analytical process with accepted methods and monitoring the results. Process evaluation studies with six-sigma and quality indicators are limited in microbiology and parasitology laboratories. We think that laboratory quality is indispensable and this study will be an example for the laboratory specialists who want to evaluate pre-analytical process of their laboratories.

15 February 2022 in Northwestern Medical Journal
Verified
Journal Article
Open access
DEDilek İrEn Emekli
Dilek İrEn Emekli
DADiler Aslan
Diler Aslan
NZNergiz Zorbozan
Nergiz Zorbozan
Aim: For the accreditation of a medical laboratory, it is necessary to evaluate the quality indicators (QI) used to evaluate pre-analytical process performance and establish an infrastructure to prevent errors arising from outside the laboratory. We aimed to present the quality indicators to prove the pre-analytical process performance of a medical (clinical) laboratory that has a large workforce prepared for medical laboratory accreditation.Methods: The sample rejection criteria were defined for the pre-analytical process. QIs, which are the requirements of the ISO15189 standard, was determined. QIs were estimated both as percentages and process Sigma levels. Pareto charts presented the distribution of errors.Results: QI values calculated as “%” and “Sigma” levels consistently demonstrated performances. According to 80% cumulated percentages, the Pareto charts rankings were “haemolysed,” “coagulated,” “barcode error,” and “insufficient” samples. In addition, when Pareto charts were evaluated, it was seen that the first 2 reasons in the 6-month period were “hemolysis” and “clotted samples” in all months. Still, the third most common reason was found to vary between “barcode error” and “insufficient” samples.Conclusion: Because of the consistency between % and sigma values, QIs can be presented with one of these in showing laboratory pre-analytical processes. However, sigma values give a more general view, and performance can be easily monitored between months. Pareto charts help illustrate error distribution and provide information for continuous improvement in laboratory-related healthcare.


1 January 2023 in Acibadem Universitesi Saglik Bilimleri Dergisi
Verified
Journal Article
Open access
PDF file
NZNergiz Zorbozan
Nergiz Zorbozan
IAİlker Akarken
İlker Akarken
ESEmre Serten
Emre Serten
EFElif Firat
Elif Firat
Purpose: This study aimed to assess the impact of hemodialysis treatment and different dialysis membranes with varying surface areas on serum levels of total prostate-specific antigen (tPSA), free prostate-specific antigen (fPSA), and the fPSA/tPSA ratio in patients undergoing hemodialysis treatment. Material and Methods: The study was conducted at the Central Laboratory of....Hospital in May, June, and July 2020. tPSA, fPSA, and fPSA/tPSA ratios measured in pre-dialysis and post-dialysis samples were determined. Correlation between pre-dialysis and post-dialysis of fPSA and tPSA levels and patients' ultrafiltrates were evaluated. The fPSA, tPSA, and fPSA/tPSA measured in pre-dialysis and post-dialysis samples grouped according to membrane type were compared. Results: The fPSA levels and fPSA/tPSA ratios of pre-dialysis samples were significantly lower than post-dialysis samples. tPSA values were not significantly different in pre-dialysis and post-dialysis samples. According to membrane types, it was found that pre-dialysis and post-dialysis tPSA, fPSA, and fPSA/tPSA were not significantly different. There was a positive correlation between difference in fPSA concentrations measured in pre-dialysis and post-dialysis samples and ultrafiltrate (rho=0.380). A positive correlation was found between difference in tPSA concentrations measured in pre-dialysis and post-dialysis samples and ultrafiltrate (rho=0.562). Conclusion: Post-dialysis fPSA values and fPSA/tPSA ratios were found to be elevated in patients receiving hemodialysis treatment due to hemoconcentration and other potential effects of dialysis. Therefore, interpreting fPSA values and fPSA/tPSA ratios in patients undergoing hemodialysis treatment according to current clinical decision limits may lead to misinterpretation. In this group of patients, the use of tPSA testing is safe as it remains unaffected by dialysis treatment.